BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) granted inducement stock options under its 2025 Inducement Plan on May 10, 2026. One new employee received options for 32,675 shares at an exercise price of $7.66 per share, vesting over four years, under Nasdaq Rule 5635(c)(4).
Details
News Market Reaction – BBOT
On May 13, the first trading day after this news, BBOT closed 0.62% below the previous close.
Data tracked by StockTitan Argus for the May 13 session.
Key Figures
- Inducement options granted
- 32,675 shares
- Non-qualified stock options under 2025 Inducement Plan to one new hire
- Option exercise price
- $7.66 per share
- Exercise price equal to Nasdaq closing price on May 10, 2026
- Par value
- $0.0001 per share
- Par value of BBOT common stock underlying the inducement options
- Initial vesting cliff
- 25% after 1 year
- One-quarter of options vest on first anniversary of employee start date
- Subsequent vesting schedule
- 36 monthly installments
- Remaining options vest in 36 equal monthly installments thereafter
- Grant date
- May 10, 2026
- Effective date of the inducement stock option grant
- Plan adoption date
- October 2025
- Board adoption month of the 2025 Inducement Plan
- Number of hires
- 1 employee
- Awards made as a material inducement to a single March 2026 hire
Historical Context
-
AACR 2026 data for pan-KRAS inhibitor BBO-11818 with strong activity.
-
New CEO, COO, and Executive Chairman appointments tied to pipeline expansion.
-
AACR data for BBO-10203 showing RAS:PI3Kα breaker activity and combinations.
-
U.S. FDA Fast Track designation for BBO-11818 in KRAS-mutant PDAC.
-
Prior inducement stock option grant to a new hire under 2025 plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
par value financial
Nasdaq Listing Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.
The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value
All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts: Investor Contact: Heather Armstrong, Head of Investor Relations BBOT Investors@BBOTx.com Media Contact: Jake Robison Inizio Evoke Comms Jake.robison@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.